Business Context and Reporting Period
Catheter Precision, Inc. (VTAK) filed a Current Report on Form 8-K dated May 5, 2025, regarding the completion of an asset acquisition. The Company formed a subsidiary, Cardionomix, Inc., in February 2025 to acquire late-stage treatment assets for acute decompensated heart failure from Cardionomic, Inc., a defunct entity. The transaction closed on May 5, 2025.
Key Financial Metrics and Transaction Terms
The filing details the consideration paid for the acquisition of patents and trademarks related to the Cardiac Pulmonary Nerve Simulation (CNPS) System. The transaction involved:
- Equity Consideration: Issuance of 1,000,000 restricted shares of Catheter Precision common stock.
- Debt Consideration: A promissory note issued by Cardionomix in the principal amount of $1.5 million.
- Note Terms: Simple interest at 4% per annum; no principal or interest payments due until maturity on May 5, 2028.
- Liquidity Status: The Company states it does not have sufficient liquidity to fund its business for the next three months without obtaining additional financing or entering into a strategic transaction.
Material Changes and Ownership Structure
Cardionomix, Inc. was established with the following ownership structure prior to the acquisition:
- Catheter Precision, Inc.: 82%
- David Jenkins (CEO/Executive Chairman): 5%
- FatBoy Capital L.P. (controlled by Mr. Jenkins): 7%
- Business associates of Mr. Jenkins: 6%
The assets were acquired on an "AS IS" and "WHERE IS" basis with no representations or warranties from the seller. The filing notes that future financing for Cardionomix will likely involve the issuance of additional securities, which is expected to reduce the Company's ownership interest, though it is anticipated to remain a majority-owned consolidated entity.
Outlook, Risks, and Management Commentary
Management is actively seeking financing to develop the acquired assets and fund ongoing operations. The filing highlights significant risks and contingencies:
- Financing Uncertainty: No guarantee exists that sufficient funds will be raised on a timely basis or at all.
- Regulatory and Development Risks: FDA review is expected to be costly and lengthy with no guarantee of approval. Pilot studies previously identified issues including nerve fatigue, unstable hemodynamics, and the need for device modifications.
- Internal Controls: The Company disclosed that its internal and disclosure controls were not effective as of March 31, June 30, September 30, and December 31, 2024, due to material weaknesses.
- Market Risks: The medical device industry is highly competitive, and the Company faces risks related to reimbursement, supply chain disruptions, and potential dilution from future equity issuances.
Investor Verification Checklist
- Verify the Company's current cash position and ability to meet obligations for the next three months given the stated liquidity shortfall.
- Review the status of the material weaknesses in internal controls and the remediation plan.
- Assess the progress of discussions with potential investors for Cardionomix and the likelihood of dilution to current shareholders.
- Examine the specific technical challenges identified in prior pilot studies (e.g., nerve fatigue, hemodynamic instability) and the plan to address them.
- Confirm the terms of the $1.5 million promissory note and the potential acceleration triggers related to insolvency events.